StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ZVRABearishEarningsnews
Materiality pending

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates

May 8, 2024, 9:22 AM EDT1 sourcesAI-analyzed

AI summary

What happened, with direct paths to the underlying reporting

Summary: - ZVRA reported a quarterly loss of $0.40 per share, beating estimates by 18.37%. - Revenues for ZVRA were $3.43 million, missing estimates by 2.70%. - ZVRA shares have decreased by 21% this year compared to the S&P 500. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings

  • Summary:
  • ZVRA reported a quarterly loss of $0.40 per share, beating estimates by 18.37%.
  • Revenues for ZVRA were $3.43 million, missing estimates by 2.70%.
  • ZVRA shares have decreased by 21% this year compared to the S&P 500.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.